Transition Bio, founded on technology and intellectual property from the Weitz lab at Harvard University and the Knowles lab at the University of Cambridge, focuses on pioneering biomolecular condensate analysis technology. The company's core mission is to revolutionize drug discovery through its Condensomics platform, which integrates advanced biophysics and artificial intelligence. Transition Bio utilizes droplet microfluidic approaches and cellular platforms to achieve precise characterization and mapping of biomolecular condensates, aiming to address intractable therapeutic targets.
Notable affiliated individuals include researchers from prestigious institutions such as Harvard University and the University of Cambridge. Transition Bio has made significant strides in developing proprietary datasets that enhance the understanding of condensate biology. These advancements have positioned the company as a leader in the field, with a growing impact on the precision and efficacy of drug discovery processes.
